LIFEMD INC (LFMD)

US53216B1044 - Common Stock

8.25  -0.25 (-2.94%)

After market: 8.25 0 (0%)

Fundamental Rating

3

Taking everything into account, LFMD scores 3 out of 10 in our fundamental rating. LFMD was compared to 40 industry peers in the Health Care Technology industry. LFMD may be in some trouble as it scores bad on both profitability and health. LFMD shows excellent growth, but is valued quite expensive already.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

LFMD had negative earnings in the past year.
In the past year LFMD had a positive cash flow from operations.
LFMD had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: LFMD reported negative operating cash flow in multiple years.

1.2 Ratios

LFMD has a Return On Assets (-43.06%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -43.06%
ROE N/A
ROIC N/A
ROA(3y)-117.88%
ROA(5y)-183.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LFMD has a better Gross Margin (88.21%) than 92.31% of its industry peers.
In the last couple of years the Gross Margin of LFMD has grown nicely.
The Profit Margin and Operating Margin are not available for LFMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.79%
GM growth 5Y2.59%

More info and screens

2

2. Health

2.1 Basic Checks

LFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFMD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LFMD has been increased compared to 5 years ago.
Compared to 1 year ago, LFMD has a worse debt to assets ratio.

2.2 Solvency

LFMD has an Altman-Z score of 0.11. This is a bad value and indicates that LFMD is not financially healthy and even has some risk of bankruptcy.
LFMD has a Altman-Z score (0.11) which is comparable to the rest of the industry.
The Debt to FCF ratio of LFMD is 2.37, which is a good value as it means it would take LFMD, 2.37 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 2.37, LFMD is doing good in the industry, outperforming 79.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.37
Altman-Z 0.11
ROIC/WACCN/A
WACC11.4%

2.3 Liquidity

A Current Ratio of 0.99 indicates that LFMD may have some problems paying its short term obligations.
LFMD has a Current ratio of 0.99. This is in the lower half of the industry: LFMD underperforms 69.23% of its industry peers.
LFMD has a Quick Ratio of 0.99. This is a bad value and indicates that LFMD is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of LFMD (0.94) is worse than 71.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.94

More info and screens

7

3. Growth

3.1 Past

LFMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.27%, which is quite impressive.
The Revenue has grown by 32.85% in the past year. This is a very strong growth!
The Revenue has been growing by 79.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)41.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.67%
Revenue 1Y (TTM)32.85%
Revenue growth 3Y59.92%
Revenue growth 5Y79%
Sales Q2Q%33.26%

3.2 Future

LFMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.30% yearly.
The Revenue is expected to grow by 32.16% on average over the next years. This is a very strong growth
EPS Next Y61.02%
EPS Next 2Y43.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.16%
Revenue Next 2Y32.16%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LFMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 220.57, LFMD can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, LFMD is valued a bit cheaper than the industry average as 71.79% of the companies are valued more expensively.
LFMD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.07.
Industry RankSector Rank
PE N/A
Fwd PE 220.57

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, LFMD is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 45.5
EV/EBITDA N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LFMD does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as LFMD's earnings are expected to grow with 43.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LFMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFEMD INC

NASDAQ:LFMD (5/31/2024, 7:00:02 PM)

After market: 8.25 0 (0%)

8.25

-0.25 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap348.89M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 220.57
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.06%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 88.21%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.99
Quick Ratio 0.94
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)41.27%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y61.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)32.85%
Revenue growth 3Y59.92%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y